Dong-A and Meiji Seika to build biosimilars plant
South Korean drugmaker Dong-A and Japan’s Meiji Seika Pharma will build a biosimilars plant in a bid to target the global Ab-based drug market.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs